{"entity":{"id":"nct06953960","kind":"trial","name":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma ","aka":[],"tldr":"A phase 1/2 trial of Daratumumab, Dexamethasone, Pomalidomide in multiple myeloma, run by AbbVie, now recruiting.","summary":"A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) is a phase 1/2 interventional study registered as NCT06953960 by AbbVie, with 325 participants planned, started 2025-07-23 and due to reach its primary completion in 2030-12. Interventions recorded: Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06953960","url":"https://clinicaltrials.gov/study/NCT06953960"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["daratumumab","dexamethasone","pomalidomide"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06953960","phase":"1/2","setting":"A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma","sponsor":"AbbVie","participation":[{"nct":"NCT06953960","source":"https://clinicaltrials.gov/study/NCT06953960","fetchedAt":"2026-10-07T16:55:19.231Z","studySha256":"4ac06746915252188cba8512f929169baa69f9d0fcc739b4b0252d32fa9a700b","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-14","leadSponsor":"AbbVie","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":325,"enrolmentType":"ESTIMATED","siteCount":50,"recruitingSiteCount":50,"countries":["Australia","Belgium","France","Germany","Israel","Italy","Japan","Poland","Portugal","Sweden","United Kingdom","United States"]}],"started":"2025-07-23","startedType":"actual","enrolled":325,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06953960/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"pomalidomide","kind":"drug","name":"Pomalidomide","route":"/drugs/pomalidomide/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}